• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach.使用功能位点相互作用指纹图谱方法描绘人类结构激酶组中的多药理学特征。
J Med Chem. 2016 May 12;59(9):4326-41. doi: 10.1021/acs.jmedchem.5b02041. Epub 2016 Mar 17.
2
Harnessing systematic protein-ligand interaction fingerprints for drug discovery.利用系统的蛋白质-配体相互作用指纹进行药物发现。
Drug Discov Today. 2022 Oct;27(10):103319. doi: 10.1016/j.drudis.2022.07.004. Epub 2022 Jul 16.
3
Structure-Based Kinase Profiling To Understand the Polypharmacological Behavior of Therapeutic Molecules.基于结构的激酶谱分析以了解治疗分子的多药性行为。
J Chem Inf Model. 2018 Jan 22;58(1):68-89. doi: 10.1021/acs.jcim.7b00227. Epub 2017 Dec 15.
4
KiSSim: Predicting Off-Targets from Structural Similarities in the Kinome.KiSSim:从激酶组中的结构相似性预测脱靶。
J Chem Inf Model. 2022 May 23;62(10):2600-2616. doi: 10.1021/acs.jcim.2c00050. Epub 2022 May 10.
5
Deep Learning Enhancing Kinome-Wide Polypharmacology Profiling: Model Construction and Experiment Validation.深度学习增强激酶组的多药物特性分析:模型构建与实验验证。
J Med Chem. 2020 Aug 27;63(16):8723-8737. doi: 10.1021/acs.jmedchem.9b00855. Epub 2019 Aug 15.
6
KinomeMETA: a web platform for kinome-wide polypharmacology profiling with meta-learning.KinomeMETA:一个基于元学习的用于进行全激酶组多药理学分析的网络平台。
Nucleic Acids Res. 2024 Jul 5;52(W1):W489-W497. doi: 10.1093/nar/gkae380.
7
GES polypharmacology fingerprints: a novel approach for drug repositioning.基因表达系列分析(GES)多药理学指纹图谱:一种药物重新定位的新方法。
J Chem Inf Model. 2014 Mar 24;54(3):720-34. doi: 10.1021/ci4006723. Epub 2014 Feb 17.
8
The kinase polypharmacology landscape of clinical PARP inhibitors.临床 PARP 抑制剂的激酶多靶性药理学特征。
Sci Rep. 2020 Feb 17;10(1):2585. doi: 10.1038/s41598-020-59074-4.
9
Exploration and Comparison of the Geometrical and Physicochemical Properties of an αC Allosteric Pocket in the Structural Kinome.结构激酶组中 αC 变构口袋的几何和物理化学性质的探索与比较。
J Chem Inf Model. 2018 May 29;58(5):1094-1103. doi: 10.1021/acs.jcim.7b00735. Epub 2018 May 4.
10
HKPocket: human kinase pocket database for drug design.HKPocket:用于药物设计的人类激酶口袋数据库。
BMC Bioinformatics. 2019 Nov 29;20(1):617. doi: 10.1186/s12859-019-3254-y.

引用本文的文献

1
Novel thiazole derivatives as effective anti-cancer agents against human osteosarcoma cell line (SaOS-2): Microwave-assisted one-pot three-component synthesis, in vitro anti-cancer studies, and in silico investigations.新型噻唑衍生物作为抗人骨肉瘤细胞系(SaOS-2)的有效抗癌剂:微波辅助一锅三组分合成、体外抗癌研究及计算机模拟研究
PLoS One. 2025 Aug 26;20(8):e0328221. doi: 10.1371/journal.pone.0328221. eCollection 2025.
2
Advances in reversible covalent kinase inhibitors.可逆共价激酶抑制剂的研究进展。
Med Res Rev. 2025 Mar;45(2):629-653. doi: 10.1002/med.22084. Epub 2024 Sep 17.
3
Comprehensive detection and characterization of human druggable pockets through binding site descriptors.通过结合位点描述符对人类可成药口袋进行全面检测和特征描述。
Nat Commun. 2024 Sep 10;15(1):7917. doi: 10.1038/s41467-024-52146-3.
4
Unveiling promising phytocompounds from Moringa oleifera as dual inhibitors of EGFR and VEGFR-2 in non-small cell lung cancer through in silico screening, ADMET, dynamics simulation, and DFT analysis.通过计算机模拟筛选、ADMET、动力学模拟和DFT分析揭示辣木中作为非小细胞肺癌中EGFR和VEGFR-2双重抑制剂的有前景的植物化合物。
J Genet Eng Biotechnol. 2024 Sep;22(3):100406. doi: 10.1016/j.jgeb.2024.100406. Epub 2024 Aug 12.
5
How Ligands Interact with the Kinase Hinge.配体如何与激酶铰链区相互作用。
ACS Med Chem Lett. 2023 Oct 9;14(11):1503-1508. doi: 10.1021/acsmedchemlett.3c00212. eCollection 2023 Nov 9.
6
Rigid Scaffolds Are Promising for Designing Macrocyclic Kinase Inhibitors.刚性支架在设计大环激酶抑制剂方面颇具前景。
ACS Pharmacol Transl Sci. 2023 Jul 7;6(8):1182-1191. doi: 10.1021/acsptsci.3c00078. eCollection 2023 Aug 11.
7
Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors.结构洞察与表皮生长因子受体酪氨酸激酶抑制剂的研发。
Molecules. 2022 Jan 26;27(3):819. doi: 10.3390/molecules27030819.
8
Structural Insights into Characterizing Binding Sites in Epidermal Growth Factor Receptor Kinase Mutants.结构洞察:鉴定表皮生长因子受体激酶突变体的结合位点。
J Chem Inf Model. 2019 Jan 28;59(1):453-462. doi: 10.1021/acs.jcim.8b00458. Epub 2019 Jan 11.
9
A benchmark driven guide to binding site comparison: An exhaustive evaluation using tailor-made data sets (ProSPECCTs).基于基准的配体结合位点比较指南:使用定制数据集(ProSPECCTs)的详尽评估。
PLoS Comput Biol. 2018 Nov 8;14(11):e1006483. doi: 10.1371/journal.pcbi.1006483. eCollection 2018 Nov.
10
Novel pharmacological maps of protein lysine methyltransferases: key for target deorphanization.蛋白质赖氨酸甲基转移酶的新型药理学图谱:靶点去孤儿化的关键
J Cheminform. 2018 Jul 21;10(1):32. doi: 10.1186/s13321-018-0288-5.

本文引用的文献

1
Historeceptomic Fingerprints for Drug-Like Compounds.类药物化合物的组织受体组学指纹图谱。
Front Physiol. 2015 Dec 18;6:371. doi: 10.3389/fphys.2015.00371. eCollection 2015.
2
Osimertinib: First Global Approval.奥希替尼:全球首次获批。
Drugs. 2016 Feb;76(2):263-73. doi: 10.1007/s40265-015-0533-4.
3
The ins and outs of selective kinase inhibitor development.选择性激酶抑制剂开发的来龙去脉。
Nat Chem Biol. 2015 Nov;11(11):818-21. doi: 10.1038/nchembio.1938.
4
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.用共价抑制剂靶向表皮生长因子受体的耐药性:一种基于结构的设计方法。
J Med Chem. 2015 Sep 10;58(17):6844-63. doi: 10.1021/acs.jmedchem.5b01082. Epub 2015 Aug 31.
5
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.小分子激酶抑制剂:FDA 批准药物分析。
Drug Discov Today. 2016 Jan;21(1):5-10. doi: 10.1016/j.drudis.2015.07.008. Epub 2015 Jul 23.
6
Panel docking of small-molecule libraries - Prospects to improve efficiency of lead compound discovery.小分子文库的对接——提高先导化合物发现效率的前景。
Biotechnol Adv. 2015 Nov 1;33(6 Pt 1):941-7. doi: 10.1016/j.biotechadv.2015.05.006. Epub 2015 May 27.
7
FDA-approved small-molecule kinase inhibitors.美国食品和药物管理局批准的小分子激酶抑制剂。
Trends Pharmacol Sci. 2015 Jul;36(7):422-39. doi: 10.1016/j.tips.2015.04.005. Epub 2015 May 12.
8
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.阿昔替尼通过独特的结合构象有效抑制 BCR-ABL1(T315I)。
Nature. 2015 Mar 5;519(7541):102-5. doi: 10.1038/nature14119. Epub 2015 Feb 9.
9
Applying thermodynamic profiling in lead finding and optimization.应用热力学分析进行先导化合物发现和优化。
Nat Rev Drug Discov. 2015 Feb;14(2):95-110. doi: 10.1038/nrd4486. Epub 2015 Jan 23.
10
Extending kinome coverage by analysis of kinase inhibitor broad profiling data.通过激酶抑制剂广泛分析数据扩展激酶组覆盖范围。
Drug Discov Today. 2015 Jun;20(6):652-8. doi: 10.1016/j.drudis.2015.01.002. Epub 2015 Jan 14.

使用功能位点相互作用指纹图谱方法描绘人类结构激酶组中的多药理学特征。

Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach.

作者信息

Zhao Zheng, Xie Li, Xie Lei, Bourne Philip E

机构信息

National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health , Bethesda, Maryland 20894, United States.

Scripps Ranch , San Diego, California 92131, United States.

出版信息

J Med Chem. 2016 May 12;59(9):4326-41. doi: 10.1021/acs.jmedchem.5b02041. Epub 2016 Mar 17.

DOI:10.1021/acs.jmedchem.5b02041
PMID:26929980
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4865454/
Abstract

Targeted polypharmacology of kinases has emerged as a promising strategy to design efficient and safe therapeutics. Here, we perform a systematic study of kinase-ligand binding modes for the human structural kinome at scale (208 kinases, 1777 unique ligands, and their complexes) by integrating chemical genomics and structural genomics data and by introducing a functional site interaction fingerprint (Fs-IFP) method. New insights into kinase-ligand binding modes were obtained. We establish relationships between the features of binding modes, the ligands, and the binding pockets, respectively. We also drive the intrinsic binding specificity and which correlation with amino acid conservation. Third, we explore the landscape of the binding modes and highlight the regions of "selectivity pocket" and "selectivity entrance". Finally, we demonstrate that Fs-IFP similarity is directly correlated to the experimentally determined profile. These improve our understanding of kinase-ligand interactions and contribute to the design of novel polypharmacological therapies targeting kinases.

摘要

激酶的靶向多药理学已成为设计高效且安全疗法的一种有前景的策略。在此,我们通过整合化学基因组学和结构基因组学数据,并引入功能位点相互作用指纹(Fs-IFP)方法,对人类结构激酶组的激酶-配体结合模式进行了大规模系统研究(208种激酶、1777种独特配体及其复合物)。获得了关于激酶-配体结合模式的新见解。我们分别建立了结合模式特征、配体和结合口袋之间的关系。我们还揭示了内在结合特异性及其与氨基酸保守性的相关性。第三,我们探索了结合模式的格局,并突出了“选择性口袋”和“选择性入口”区域。最后,我们证明Fs-IFP相似性与实验确定的概况直接相关。这些增进了我们对激酶-配体相互作用的理解,并有助于设计针对激酶的新型多药理学疗法。